Patients with aggressive ATLL have an extremely poor prognosis because these neoplasms are resistant to conventional chemotherapy. 2 Recently, Ishida et al. reported promising outcomes of treatment with a new agent, namely anti-CC chemokine receptor 4 (CCR4) MoAb (mogamulizumab), a nextgeneration humanized IgG1 Ab with a defucosylated Fc region. This drug markedly enhances Ab-dependent CC (ADCC) through an increased binding affinity to the Fcg receptor on effector cells in patients with ATLL relapse.
3 CCR4 is a chemokine receptor expressed on helper T cells, regulatory T cells (Tregs) 4 and certain types of T-cell neoplasms such as ATLL. 5 Mogamulizumab has been approved in Japan for the treatment of relapsed or refractory ATLL. Phase II development is underway for ATLL and cutaneous T-cell lymphoma in the United States, and for peripheral T-cell lymphoma in the United States and Europe. Moreover, mogamulizumab induces only ADCC activity, not complementdependent cytotoxicity or direct effects. Although mogamulizumab is now available in Japan for patients with ATLL, allogeneic hematopoietic SCT (allo-HSCT) remains the only curative treatment because of its ability to induce an immunological reaction. 6 The 3-year OS rate following allo-HSCT in ATLL patients is reportedly 30-40%. 6 However, relapse remains the major cause of treatment failure in patients undergoing allo-HSCT. Although mogamulizumab can be effective for patients with ATLL that relapses after allo-HSCT, the possibility of GVHD exacerbation due to the decreased number and/or impaired function of Treg remains unknown. In addition, it is unclear whether mogamulizumab can function in the early posttransplantation period, when ADCC effector cells, such as natural killer (NK) cells, are not fully reconstituted. Here we report the case of a 66-year-old patient who was treated with mogamulizumab for ATLL relapse after allo-HSCT and has sustained CR.
In January 2012, a 66-year-old Japanese male patient presented to us with enlarged systemic lymph nodes and abnormal peripheral blood lymphocytes. Based on these findings, he was diagnosed with the acute type of ATLL according to the criteria of the Japanese Lymphoma Study Group. He underwent one cycle of the CHOP chemotherapy (CY, hydroxydaunorubicin, vincristine and prednisolone) and two cycles of CHOP-VMMV 400 mg/m 2 of CY on day 1, 1 mg/m 2 of vincristine on day 1, 400 mg/m 2 of hydroxydaunorubicin on day 1, 35 mg/m 2 of etoposide on days 1-7, 40 mg/m 2 of prednisolone on days 1-3, 7 mg/m 2 of mitoxantrone on day 8, 50 mg/m 2 of ranimustine on day 8, 2 mg/m 2 of vindesine on day 8 and 40 mg/m 2 of prednisolone on days 8-10 chemotherapy. Although the size of his lymph nodes markedly decreased after this treatment, CR was not achieved. In April 2012, he received a reduced-intensity conditioning regimen comprising 4 Gy of TBI, 125 mg/m 2 of fludarabine and 80 mg/m 2 of melphalan, followed by umbilical cord blood transplantation (UCBT). Prophylaxis for GVHD included tacrolimus and mycophenolate mofetil. Although rapid engraftment was achieved by day 14 after UCBT, lymphadenopathy persisted. Chimerism analysis on day 19 demonstrated that his BM cells were 98.6% donor-derived. On day 21, the patient developed diarrhea and was diagnosed with grade II acute GVHD on the basis of colonic mucosal biopsy. Administration of prednisolone resulted in gradual clinical improvement in the GVHD. Immunosuppressant therapy was then tapered to induce a graft-versus-ATLL effect. However, 61 days after UCBT, ATLL cells reappeared in the peripheral blood and multiple cutaneous nodules developed all over his body. In addition, his serum lactate dehydrogenase elevated during this period. The patient was diagnosed with relapsed ATLL on the basis of skin biopsy. ATLL cells in the peripheral blood and biopsied skin specimens were positive for CCR4. On day 62, the patient was administered 100 mg/m 2 etoposide, which resulted in a decrease in the number of ATLL cells; however, the cutaneous nodules continued to expand. Therefore, on day 69, i.v. mogamulizumab was initiated at 1.0 mg/kg once a week. 3 Remarkably, the cutaneous nodules shrank in size immediately after the first mogamulizumab treatment cycle. Simultaneously, the systemic lymphadenopathy began to decrease and ATLL cells began to disappear from the peripheral blood. Human T-cell lymphotropic virus type 1 DNA (tax-specific primers) was eventually undetectable on day 96 after UCBT. However, after four cycles of mogamulizumab treatment, on day 91 new skin eruptions appeared on the upper extremities and spread over the entire body. Pathological examination of biopsy specimens confirmed grade II acute GVHD, but there were no signs of ATLL recurrence. Although acute GVHD was transiently exacerbated, it was confined to the skin and did not require further immunosuppressive treatment. Thereafter, the ATLL lesions continued to decrease simultaneously with the occurrence of GVHD. The patient received eight courses of mogamulizumab treatment and has been alive in CR for 6 months after UCBT.
To our knowledge, this is the first report to document successful treatment outcomes with mogamulizumab in a patient with ATLL that relapsed after allo-HSCT. In the setting of allo-HSCT, mogamulizumab may work via the direct antitumor effects of CCR4 þ tumor cells; in addition, it can also induce a graft-versus-ATLL effect by causing a decreasing Treg function. 7 In our patient, the number of ATLL lesions markedly decreased immediately after the initiation of treatment with mogamulizumab. As the course of treatment progressed, the remaining ATLL lesions gradually decreased concomitant with the occurrence of GVHD, which was presumably induced by mogamulizumab. There are two significant questions concerning mogamulizumab treatment after allo-HSCT.
First, how effective is mogamulizumab treatment in the early phase after allo-HSCT? Mogamulizumab has a potent ADCC effect on target cells through binding of Ag-specific NK cells to FcgRIIIa. Therefore, the reconstitution status of NK cells after allo-HSCT can be expected to influence the therapeutic effects of mogamulizumab in the early phase after transplantation. Previous immunophenotypic analysis has shown that NK cells are usually the first class of lymphocytes to recover after allo-HSCT, with normalization of NK cell count occurring by 3-6 months even after UCBT, which is typically associated with slower hematolymphopoiesis compared with BM or PBSC transplantation. 8 In our case, the proportion of NK cells (CD56 þ and CD16 þ cells) among the lymphocytes was 11.8% (0.09 Â 10 9 /L) on day77 (after two cycles of mogamulizumab), and 41.9% (0.27 Â 10 9 /L) on day 96 (after four cycles of mogamulizumab) as per flow cytometric analysis (Figure 1 ). Therefore, mogamulizumab may have worked in conjunction with the gradual reconstitution of NK cells after UCBT in this case.
The second issue is the possibility of GVHD exacerbation because of decreased Treg after mogamulizumab treatment. Decreased Treg activity because of mogamulizumab treatment reportedly enhanced ADCC in vivo in a humanized mouse model. 7 In addition, the occurrence and severity of GVHD is known to be closely associated with low Treg frequency. 9 Accordingly, a decrease in Treg frequency induced by post-transplantation anti-CCR4 MoAb treatment can be expected to enhance the allogeneic immune response and aggravate GVHD. In our case, on day 62, the number of CD4 þ 25 þ cells (including ATLL cells and Treg) was 0.022 Â 10 9 /L, and this decreased to 0.002 Â 10 9 /L and 0.010 Â 10 9 /L after second and fourth cycles of mogamulizumab treatment (on day77 and day 96, respectively) ( Figure 1 ). Although acute GVHD was transiently exacerbated in our case, it was confined to the skin, alleviating the need for further immunosuppressive treatment. Furthermore, the remaining ATLL lesions responded to the occurrence of GVHD, resulting in gradual improvement via the so-called graft-versus-ATLL effect. Recently, Kanda, et al. 10 reported that the development of mild-to-moderate acute GVHD confers a beneficial influence on survival of ATL patients who received allo-HSCT. Therefore, during mogamulizumab treatment after allo-HSCT, it is crucial to avoid excessive GVHD exacerbation and preserve the graft-versus-ATLL effect at the same time. Further large-scale studies are required to assess the efficacy and safety of anti-CCR4 MoAb treatment for ATLL that relapses after allo-HSCT. 
